ArticleBMC immunology2017
Experimental validation of the RATE tool for inferring HLA restrictions of T cell epitopes.
Article in BMC immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Comprehensive mapping of human CD4Cell reports. Medicine · 2026Article
- COMBO-RATE: An experimentally validated bioinformatic tool to identify promiscuous HLA restrictions.bioRxiv : the preprint server for biology · 2026Article
- Article
- Liver stage P. falciparum antigens highly targeted by CD4+ T cells in malaria-exposed Ugandan children.PLoS pathogens · 2025Article
- Immunodominant MHC-II (Major Histocompatibility Complex II) Restricted Epitopes in Human Apolipoprotein B.Circulation research · 2022Article
- Article
- Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022Review
- Application 2D Descriptors and Artificial Neural Networks for Beta-Glucosidase Inhibitors Screening.Molecules (Basel, Switzerland) · 2020Article
- Identification and Characterization of CD4Journal of virology · 2020Article
- Epitope prediction and identification- adaptive T cell responses in humans.Seminars in immunology · 2020Review
- CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection.Frontiers in immunology · 2020Article
- IEDB-AR: immune epitope database-analysis resource in 2019.Nucleic acids research · 2019Article
- Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 496 adults from San Diego, California, USA.Human immunology · 2018Article
- Allergen and Epitope Targets of Mouse-Specific T Cell Responses in Allergy and Asthma.Frontiers in immunology · 2018Article
- A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models forFrontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe RATE tool was recently developed to computationally infer the HLA restriction of given epitopes from immune response data of HLA typed subjects without additional cumbersome experimentation.
resultsHere, RATE was validated using experimentally defined restriction data from a set of 191 tuberculosis-derived epitopes and 63 healthy individuals with MTB infection from the Western Cape Region of South Africa. Using this experimental dataset, the parameters utilized by the RATE tool to infer restriction were optimized, which included relative frequency (RF) of the subjects responding to a given epitope and expressing a given allele as compared to the general test population and the associated p-value in a Fisher's exact test. We also examined the potential for further optimization based on the predicted binding affinity of epitopes to potential restricting HLA alleles, and the absolute number of individuals expressing a given allele and responding to the specific epitope. Different statistical measures, including Matthew's correlation coefficient, accuracy, sensitivity and specificity were used to evaluate performance of RATE as a function of these criteria. Based on our results we recommend selection of HLA restrictions with cutoffs of p-value < 0.01 and RF ≥ 1.3. The usefulness of the tool was demonstrated by inferring new HLA restrictions for epitope sets where restrictions could not be experimentally determined due to lack of necessary cell lines and for an additional data set related to recognition of pollen derived epitopes from allergic patients.
conclusionsExperimental data sets were used to validate RATE tool and the parameters used by the RATE tool to infer restriction were optimized. New HLA restrictions were identified using the optimized RATE tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.